CELZ - Creative Medical surges ~150% after diabetes therapy CELZ-001 shows promise in trial

2023-04-12 09:14:56 ET

• Creative Medical Technology ( NASDAQ: CELZ ) stock soared ~150% premarket on Wednesday after the company said that one-year follow-up data confirmed significant efficacy and no serious adverse effects in patients using CELZ-001 to treat Type 2 Diabetes.
• There were 30 patients in the study, 15 received CELZ-001 and the remaining received optimized medical therapy.
• The company said that at one year, there was an overall efficacy of 93% in the treated patients showing at least a 50% reduction in insulin requirement.
• There were no safety concerns related to CELZ-001 at one year follow-up using the same infusion procedure as in the currently U.S. FDA cleared CELZ-201 clinical trial, the company added.
• Creative Medical plans to further develop this program and present the data at an upcoming endocrinology conference.
• "The positive one-year data from our Type 2 diabetes study is very encouraging, and we are excited to engage with clinicians in further translation," said Creative Medical's President and CEO Timothy Warbington.
• CELZ +152.07% to $1.22 premarket April 12

For further details see: